15-40807371-C-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_001077268.2(ZFYVE19):c.-219C>G variant causes a 5 prime UTR premature start codon gain change. The variant allele was found at a frequency of 0.00000805 in 1,614,162 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0000068 ( 0 hom. )
Consequence
ZFYVE19
NM_001077268.2 5_prime_UTR_premature_start_codon_gain
NM_001077268.2 5_prime_UTR_premature_start_codon_gain
Scores
6
12
Clinical Significance
Conservation
PhyloP100: 4.94
Genes affected
ZFYVE19 (HGNC:20758): (zinc finger FYVE-type containing 19) Enables phosphatidylinositol-3-phosphate binding activity. Involved in abscission; mitotic cytokinesis checkpoint signaling; and negative regulation of cytokinesis. Located in centrosome; cleavage furrow; and midbody. [provided by Alliance of Genome Resources, Apr 2022]
DNAJC17 (HGNC:25556): (DnaJ heat shock protein family (Hsp40) member C17) Predicted to enable RNA binding activity. Predicted to act upstream of or within negative regulation of transcription by RNA polymerase II and toxin transport. Predicted to be located in cytoplasm and nucleus. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ZFYVE19 | NM_001077268.2 | c.-219C>G | 5_prime_UTR_premature_start_codon_gain_variant | 1/11 | ENST00000355341.8 | NP_001070736.1 | ||
DNAJC17 | NM_018163.3 | c.76G>C | p.Glu26Gln | missense_variant, splice_region_variant | 1/11 | ENST00000220496.9 | NP_060633.1 | |
ZFYVE19 | NM_001077268.2 | c.-219C>G | 5_prime_UTR_variant | 1/11 | ENST00000355341.8 | NP_001070736.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ZFYVE19 | ENST00000355341 | c.-219C>G | 5_prime_UTR_premature_start_codon_gain_variant | 1/11 | 1 | NM_001077268.2 | ENSP00000347498.4 | |||
DNAJC17 | ENST00000220496.9 | c.76G>C | p.Glu26Gln | missense_variant, splice_region_variant | 1/11 | 1 | NM_018163.3 | ENSP00000220496.4 | ||
ZFYVE19 | ENST00000355341 | c.-219C>G | 5_prime_UTR_variant | 1/11 | 1 | NM_001077268.2 | ENSP00000347498.4 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152268Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
3
AN:
152268
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000684 AC: 10AN: 1461894Hom.: 0 Cov.: 31 AF XY: 0.00000550 AC XY: 4AN XY: 727248
GnomAD4 exome
AF:
AC:
10
AN:
1461894
Hom.:
Cov.:
31
AF XY:
AC XY:
4
AN XY:
727248
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152268Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74398
GnomAD4 genome
AF:
AC:
3
AN:
152268
Hom.:
Cov.:
33
AF XY:
AC XY:
0
AN XY:
74398
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 06, 2023 | The c.76G>C (p.E26Q) alteration is located in exon 1 (coding exon 1) of the DNAJC17 gene. This alteration results from a G to C substitution at nucleotide position 76, causing the glutamic acid (E) at amino acid position 26 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D
M_CAP
Benign
D
MetaRNN
Uncertain
D;D
MetaSVM
Benign
T
MutationAssessor
Benign
L;.
PROVEAN
Benign
N;.
REVEL
Benign
Sift
Benign
T;.
Sift4G
Benign
T;T
Polyphen
B;.
Vest4
MutPred
Gain of MoRF binding (P = 0.0235);Gain of MoRF binding (P = 0.0235);
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at